Twitcher mouse is a murine model of human globoid cell leukodystrophy (Krabbe disease), which is characterized by a genetic deficiency in galactocerebrosidase (GALC) activity. The nervous system is affected early and severely by demyelination in the white matter. So far, there is no effective treatment for Krabbe disease except bone marrow transplantation (BMT). However, BMT has inherent limitations such as unavailability of donors and graft-versus-host disease. In this study, we injected recombinant adenovirus encoding GALC into the lateral ventricle of twitcher mice at postnatal day 0 (PND 0) and the therapeutic effects were evaluated. Our results showed slight, but significant
Introduction
Most lysosomal storage diseases mainly involve the nervous system. In some of these diseases, such as TaySachs disease, type 2 Gaucher disease and Krabbe disease, the neuropathological changes start early, progress rapidly and cause the patient's death at an early age. Therapies to these diseases as early as the minimal pathological changes take place or before the clinical symptoms become apparent may be of great importance in the improvement of these diseases.
The twitcher mouse is a suitable model for the trials of neonatal therapy to these genetic diseases. It is a murine model of a metabolic demyelinating disorder, globoid cell leukodystrophy (GLD, Krabbe disease) in human, 1 caused by a genetic defect in the activity of galactocerebrosidase (GALC, EC 3.2.1.46). 2 The clinical symptoms of the twitcher mouse include failure to gain weight, inactivity and tremor from postnatal day (PND) 15 to 20 and progressive paralysis of hind limbs from around PND 35. After PND 35, all these symptoms develop rapidly and the mice usually die around PND 40. An increasing infiltration of PAS-positive macrophages concomitant with demyelination is the characteristic neuropathological finding in the twitcher mouse. The pathological process improvements in motor functions, body weight and twitching and a prolonged life span. In brain, GALC activity was increased to 15% that of normal littermates and psychosine concentration was decreased to 55% that of untreated twitcher mice at PND 15. The number of PAS-positive globoid cells in brain stem was also reduced significantly at PND 35. In contrast, when adenoviruses were injected to the twitcher mice at PND 15, almost no improvements were observed. These results demonstrate that the timing of treatment may be of great importance in Krabbe disease. Gene Therapy (2001) 8, 1081-1087.
is well correlated with the progression of neurological symptoms. 3 In addition, galactosylsphingosine (psychosine), a cytotoxic metabolite and one of the substrates of GALC, accumulates in both the central and peripheral nervous system (CNS and PNS). Psychosine is considered primarily responsible for the devastating neuropathology in GLD. [4] [5] [6] Bone marrow transplantation (BMT) was attempted as the therapy to the twitcher mouse and human GLD patients. Prolonged life span and improved neuropathology in the recipient twitcher mice 7, 8 had been achieved. Significant improvements were also observed in the patients with GLD after BMT especially in the patients of the late-onset form. 9 However, the disadvantages of BMT such as shortage in donor supply and the side-effects largely limit the clinical application of this treatment. With the success in the cloning of GALC cDNA and the identification of gene mutation in twitcher, [10] [11] [12] gene therapy of the twitcher mouse became possible and challenging.
The goal of this study is to elucidate the importance of timing of the treatment to the twitcher mouse and evaluate the effectiveness of the intraventricular route in gene transfer to the CNS at the neonatal period.
We show in this study that intraventricular administration of recombinant adenovirus expressing a human GALC to neonatal twitcher mouse leads to significant improvements in the clinical, biochemical and pathological phenotypes. The time point of viral injection is critical for the efficacy of the therapy to the twitcher mouse.
Results
Clinical symptoms were improved in the twitcher mice that received AxCAGALC injection at PND 0, but not in those that received it at PND 15 We monitored the clinical symptoms of the twitcher mice in the treated and control groups daily from PND 16, because the twitcher mice are indistinguishable from their normal littermates until PND 15. As controls, we monitored clinical status of twitcher mice who received AxCALacZ at PND 0 and twitcher mice without any injection. There were no significant changes between the twitcher mice that received AxCALacZ injection and the untreated twitcher mice. This result suggests that adenoviral vector injection itself does not alter the disease course. Improvements in the general status and twitching were seen in the twitcher mice that received AxCAGALC at PND 0 (PND 0-GALC group) compared with the control twitcher mice after PND 16.
The mice in PND 0-GALC group showed improved feeding behavior and were more active. The motor functions were also improved. We observed that most of them could climb up to the top of the cage until hind limbs were completely paralyzed after PND 35. This was never seen in the untreated twitcher mice in our laboratory. After PND 35, although the mice in PND 0-GALC group became less active and encountered difficulties in food and water intake as the control twitcher mice do, all these symptoms were less severe. No significant improvement of these symptoms was seen in the twitcher mice that received AxCAGALC at PND 15 (PND 15-GALC group) compared with the control twitcher mice. Significant increase in body weight was observed in the PND 0-GALC group over the age-matched control twitcher although a weight loss was seen after PND 35 (Figure 1 ). No such increase was observed in the PND 15-GALC group.
The onset of twitching in PND 0-GALC group was significantly delayed (21.3 ± 1.2 to 24.3 ± 1.7, P Ͻ 0.02) and the severity of twitching at PND 30 and PND 35 was reduced (5.0 ± 1.0 to 3.5 ± 0.5, P Ͻ 0.003) compared with the twitcher mice who received AxCALacZ at PND 0. No improvement on the severity and onset of twitching was observed in PND 15-GALC group. The life span was extended in the PND 0-GALC group with a significant difference from that in the untreated twitcher mice (40.2 ± 1.3 to 43.2 ± 2.7, P Ͻ 0.05). In one case, the treated twitcher lived up to PND 48 while the untreated twitcher in our laboratory never lived beyond PND 42. No significant change in life span was observed in PND 15-GALC group. There was no change in the onset of paralysis of hind limbs among all each groups. The summary of clinical symptoms of treated and untreated twitcher mice are shown in Table 1 .
Increased GALC activity and decreased psychosine concentration in brain were seen in PND 0-GALC group The PND 0-GALC group showed a significant increase in GALC activity in the whole brain extracts both at PND 15 (0.07 ± 0.03 to 0.92 ± 0.21 nmol/h/mg, P Ͻ 0.003) and PND 35 (0.09 ± 0.03 to 0.39 ± 0.11 nmol/h/mg, P Ͻ 0.02) compared with the untreated twitcher. An increase of GALC activity was also observed in PND 15-GALC group at PND 35 ( Figure 2 ). In PND 0-GALC group psychosine concentration in the brain decreased to approxi- 
24.3 ± 1.7 (11) 3.5 ± 0.5 (11) 4.6 ± 0.5 (11) 43.2 ± 2.7 (6) 36.1 ± 1.1 (9) Figure 6 ), but not for 2Ј,3Ј-cyclic nucleotide 3Ј-phosphodiesterase (CNPase) and microtubule-associated protein (MAP2) (data not shown), while ␤-gal-positive cells with long processes in the third ventricle were negative for any of these markers (data not shown).
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Discussion
This study demonstrates two important points: necessity of neonatal treatment in the twitcher mouse and usefulness of the intraventricular route in the gene transfer at the neonatal period.
Clinicopathological improvements were achieved in the twitcher mice that received AxCAGALC injection at PND 0, but not in the twitcher mice that received it at PND 15. This indicates that the therapy to the twitcher mouse must be initiated as early as when the minimal pathological changes take place or before the clinical symptoms become apparent. In the twitcher mouse, no noticeable neurological symptoms and characteristic neuropathological changes such as infiltration of PASpositive macrophages or demyelination were observed in the brain up to PND 15. 3 However, other changes such as increased number of GFAP immunoreactive cells 13 and the inclusion bodies in oligodendrocytes 14 in the telencephalon and the spinal cord were detectable as early as PND 5-10. Psychosine accumulation was also reported to occur as early as PND 7, 5 but all these changes are still mild at this early period. It is possible that the progression of pathology could be corrected or delayed by the gene transfer of GALC to the CNS at the neonatal period when the neuropathological changes are still mild and the brain is retaining a high reconstruction capacity. The clinicopathological improvements achieved in the twitcher mice receiving AxCAGALC injection at PND 0 may be due to the degradation of psychosine by the transduced enzyme in the CNS. Psychosine is reported to inhibit protein kinase C activity and cause the dysfunction of intracellular signal transduction 15, 16 and is considered to play a major role in the pathogenesis of GLD. Since psychosine accumulation in the early stage is still mild, the transferred GALC could be sufficient to degrade it and consequently delay neuropathological progression and lead to improvements in the clinical symptoms. However, at PND 15-20, the clinical symptoms occur and the typical pathological abnormalities are already formed. 3 The neurological deterioration progresses rapidly and the damage in the CNS is irreversible. Thus, it is difficult to repair the damage and control the neuropathological progression when GALC was transferred at PND 15.
The results also indicate that the intraventricular route of gene transfer to the CNS at the neonatal period is effective. The improved neuropathology may result from excretion of the transduced gene product by the ependyma to brain parenchyma. It is known that most lysosomal enzymes can be secreted from normal or overexpressing cells and taken up by enzyme-deficient cells (cross-correction). The free enzyme binds to intracellular mannose 6-phosphate (Man-6-P) receptors, which deliver enzyme to the lysosomes. 17 Evidence for the transfer of excreted GALC from retrovirally transduced overexpression cells to fibroblasts of patients with Krabbe disease was reported previously 18 and this uptake was considered to partially involve Man-6-P receptors. Thus, when AxCAGALC was injected into the ventricle, the transgene product GALC might be secreted from the ependyma and spread to the surrounding brain parenchyma far beyond the ependymal layer of the detected LacZ-positive regions. It is known that LacZ is essentially not excreted from cells. In addition, we observed many LacZ-positive cells with long processes around the ventricle in the PND 0-LacZ group. These cells may play an important role in spreading transduced GALC product much wider through the long processes to the region far from the ventricle and the neuropathology in these regions may be corrected. The significant decrease in psychosine concentration at PND 15 in PND 0-GALC group indicates the relatively widely spread of GALC protein in CNS at an early stage. However, the identity of these cells is still not clear. Although the cells around the lateral ventricle were GFAP-positive, the morphology did not conform to that of astrocytes. The morphology of the long processes presented in these cells showed that they might be tanycytes, a special cell of the ependyma. The identification of the type and the features of these cells is underway. Few of these cells were observed in the PND 15-LacZ group. The reason is unknown. It may be due to the relatively mature brain-CSF (cerebrospinal fluid) barrier at PND 15 which inhibited the infection of these cells with virions. When AxCAGALC was injected to the twitcher mice at PND 15, the distribution of the transduced GALC product may be relatively restricted and this may be another reason for the failure in achieving improvements in the PND 15-GALC group.
As a route of administration of viral vector to the CNS, the intravenous route was previously reported in the treatment of MPS VII mouse using adeno-associated viruses and a widespread distribution and persistent expression of the transgene in the CNS had been achieved. 19 In the initial study we attempted intravenous injection of AxCAGALC to newborn twitcher mice and no significant increase of GALC activity in the brain of the recipient twitcher mice could be detected, although GALC activity in the liver was drastically increased. The clinical symptoms also did not improve. The reason is unknown. It may be due to the properties of the different viruses used or the unknown neuroanatomical features that are different between the two animal models. In this study, we used the intraventricular route for gene transfer to the CNS. An effective and persistent expression of the transgene was achieved. This indicates that the intraventricular route is effective for gene transfer at the neonatal period.
Although significant clinical improvements in the PND 0-GALC group could be observed up to PND 35, the deterioration progressed thereafter. With the appearance of inactivity, and weight loss, the life span of the mouse was not prolonged much, despite the continuing expression of the transgene. This may be attributed to the natural course of the disease which progressed rapidly resulting from the drastically accelerated accumulation of psychosine in the CNS after PND 25-35. 5 In addition, the complete paralysis of hind limbs after PND 35 largely restricted the movements of body and food and water intake of the mice and caused further deterioration of the disease. Despite the improvements achieved at the early stage, the treatment appeared insufficient to prevent the progression of this disease, which shows the difficulty in treating this rapidly progressing leukodystrophy.
The results indicate the critical importance of early treatment in lysosomal storage disorders with an early and severe CNS involvement and the utility of the intraventricular route in the neonatal period. However, it must be taken into consideration that the results showing the difference in the timing of treatment (differences between PND 0 and PND 15-GALC groups in this study) cannot be directly applied in the gene therapy of human patients, because the developmental phases of the brain are not comparable between rodents and human. The brain of neonatal rodents are much more immature than that of human neonates. The developmental stage of the human neonatal brain is already at the beginning of the active myelination period corresponding to the 15-20-day-old rodent brains. If it is necessary to initiate the treatment during the neonatal period of the mouse, intrauterine treatment would be necessary for humans. We are also aware of the limitation of this approach, such as the transient nature of gene expression by adenoviral vector. However, if we can prevent disease progression in the early stages by this treatment, BMT in the later stage may be more effective in patients with Krabbe disease, especially in the infantile form.
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Materials and methods
GALC cDNA cloning
The cloning of human GALC cDNA was performed by RT-PCR based on cDNA sequences previously reported. 10, 11 Total RNA was extracted from primary human skin fibroblasts using RNeasy Kit (Qiagen, Hilden, Germany). RT-PCR was performed using RNA LA PCR kit (TaKaRa, Osaka, Japan). After the synthesis of the first strand cDNA with reverse transcriptase (AMV) and Oligo dT-Adaptor primer, PCR was performed with the specific primers for human GALC (sense, 5Ј-ATCGGATCCATGACTGCGGCCGCGGGTTCG-3Ј; antisense, 5Ј-ATCGGTACCTAAGTATTAGCGTGTG GCTTC-3Ј) with LA Taq kit (TaKaRa).
Construction of recombinant adenovirus expressing human GALC and preparation of adenovirus vectors
The amplified PCR products of GALC cDNA were blunted with T4 DNA polymerase (DNA Blunting Kit, TaKaRa) and inserted into the SwaI site of the adenovirus expression vector (pAxCAwt) between CAG (cytomegalovirus-enhancer-chicken-actin hybrid) promoter 20 and rabbit ␤-globin polyadenylation signals. Recombinant adenovirus expressing GALC (AxCAGALC) was isolated as previously described. 21 A recombinant adenovirus encoding E. coli ␤-galactosidase (AxCALacZ) was the generous gift of Dr I Saito (University of Tokyo, Japan). 22 Adenoviruses were purified and titered as previously described. 23 The final titers of AxCAGALC and AxCALacZ were 3.9 × 10 9 and 3.4 × 10 9 p.f.u./ml, respectively.
Animal preparation
Breeding pairs of twitcher heterozygotes (twi/+) were purchased from Jackson Laboratory (Bar Harbor, ME, USA). The genotypes were determined around PND 5 to 7 by a PCR method using DNA extracted from mouse tail. 12 Forty-seven twitcher mice (twi/twi) were divided into four groups: 15 mice received AxCAGALC injection intraventricularly at PND 0 (PND 0-GALC group); 15 received AxCAGALC injection at PND 15 (PND 15-GALC group); three received AxCALacZ injection at PND 0 and 14 untreated twitcher mice were taken as controls. Six normal mice received AxCALacZ injection at PND 0 (PND 0-LacZ group) and three at PND 15 (PND 15-LacZ group).
Intraventricular injection
The newborn mice injected at PND 0 were immobilized by hand and 5 l of AxCAGALC (1.9 × 10 7 p.f.u.) or AxCALacZ (1.7 × 10 7 p.f.u.) was injected slowly into the lateral ventricle through a 30 G needle with a Hamilton syringe. The mice injected at PND 15 were anesthetized with Nembutal (25 g/g BW) intraperitoneally, placed in a stereotactic apparatus (Narishige, Tokyo, Japan), 5 l of AxCAGALC or AxCALacZ was injected slowly into the lateral ventricle at a point 1 mm caudal to bregma, 0.5 mm lateral to saggital suture, 1.5 mm in depth.
Assessment of clinical symptoms
The general status (activity, feeding, body weight and life span), twitching and paralysis of the hind limbs of the twitcher mice in the treated and control groups were monitored daily after PND 16 without prior knowledge of treatment status. The scoring system for assessment of severity of the twitching was modified from the system previously described 24 and presented in two parameters. Frequency: 1, rare; 2, intermittent; 3, constant; and severity; 1, fine; 2, mild; 3, mild moderate; 4, moderate; 5, severe. The final score is the sum of the two parameters.
Galactocerebrosidase assay GALC activities of the whole brain of treated and control mice were assayed at PND 15 or 35 (n = 3) as previously described. 25 In brief, the brain was homogenized in 10 volumes of distilled water with a Potter-Elvehjem homogenizer, sonicated, and centrifuged at 1120 g for 10 min. The supernatant were collected and used for the assay. Protein concentrations were determined with BCA protein assay reagent (Pierce) with bovine albumin as standard.
HPLC analysis of psychosine
Psychosine concentrations of whole brain were measured by HPLC as described previously 26 using the remaining homogenates from GALC activity assay.
Neuropathological analysis
At PND 35, the twitcher mice in the treated and untreated groups (n = 3) were anesthetized with ether and fixed by transcardial perfusion of chilled 4% paraformaldehyde in 0.1 m phosphate buffer (PB, pH 7.4). The brains were removed and immersed in the same fixative overnight at 4°C, then washed in 0.1 m PB (pH 7.4), sliced coronally and embedded in paraffin. Serial sections were cut in the brain stem at a thickness of 4 m. After being deparaffinized and hydrated, every fifth section was used for PASstaining. The number of PAS-positive cells in the brain stem were counted under light microscopy, and the average number per section was compared among the treated and untreated twitcher mice. Cells from 24 sections were counted per animal.
LacZ staining and immunohistochemistry
The mice in the PND 0-LacZ group at PND 35 or 60 (n = 3) and PND 15-LacZ group at PND 18 (n = 3) were anesthetized with ether and perfusion fixed transcardially with chilled 4% paraformaldehyde, 0.1% glutaraldehyde in 0.1 m PB (pH 7.4). The brains were postfixed in the same fixative overnight at 4°C and cryoprotected in 15% sucrose in 0.1 m PB. Sections were sliced at a thickness of 40 m using a cryostat and one out of 10 sections was stained overnight at 37°C with LacZ staining solution (1 mg/ml X-gal, 5 mm potassium ferricyanide, 5 mm potassium ferrocyanide and 2 mm MgCl 2 in PBS(−)). The next few sections were used for double immunostaining of E. coli ␤-galactosidase (␤-Gal) together with some neural cell markers. The primary antibodies used were rabbit polyclonal anti-␤-gal (5 prime → 3 prime Inc, Boulder, CO, USA; 1:100 dilution), rat monoclonal anti-GFAP (kindly provided by Dr V Lee, 27 University of Pennsylvania, 1:10 dilution), mouse monoclonal anti-CNPase (Sigma, St Louis, MO, USA; 1:100 dilution) and mouse monoclonal anti-MAP2 (Lab Vision, Fremont, CA, USA; 1:50 dilution). The sections were incubated for 30 min in 0.1 m PB containing 0.3% Triton X-100 (PBST) and for 1 h with 10% normal goat serum (NGS) in PBST. After being incubated for 2 days with primary antibodies diluted with 3% NGS in PBST at 4°C, sections were reacted with FITC-conjugated goat anti-rabbit IgG and rhodamineconjugated rabbit anti-rat IgG or goat anti-mouse IgG (Cappel, Aurora, OH, USA), diluted 1:100 with 3% NGS in PBST for 1 h at room temperature.
Statistical analysis
A two-tailed Student's t test was used to compare the significance. The data are presented as mean ± s.d.
